Metastatic collecting duct (Bellini duct) carcinoma: A case report.
- Author:
Ji Eun LEE
1
;
Hye Sung WON
;
Jin Hyoung KANG
;
Yeong Seon HONG
;
Soon Nam OH
;
Tae Jung KIM
;
Yoon Ho KO
Author Information
1. Department of Internal Medicine, The Catholic University of Korea College of Medicine, Seoul, Korea. koyoonho@catholic.ac.kr
- Publication Type:Case Report
- Keywords:
Collecting duct carcinoma;
Neoplasm metastasis;
Antineoplastic agents
- MeSH:
Antineoplastic Agents;
Carcinoma, Renal Cell;
Consensus;
Disease Progression;
Doxorubicin;
Drug Therapy, Combination;
Humans;
Liver;
Lung;
Male;
Middle Aged;
Neoplasm Metastasis;
Prognosis;
Vincristine
- From:Korean Journal of Medicine
2009;77(6):780-786
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
Renal cell carcinoma accounts for 2.6% of all cancer, and most renal cell carcinoma has a clear cell origin. Bellini duct carcinoma, which arises from collecting duct cells (Bellini cells), is a rare type of renal cell carcinoma, constituting less than 1% of all renal cell carcinoma. The prognosis of Bellini duct carcinoma is very poor, and more than 60% of the patients die within 2 years of diagnosis. There is no consensus regarding the optimal treatment. We report a case of Bellini duct carcinoma in a 53-year-old male with multiple lung and liver metastases. The patient was treated with eight cycles of M-VAC (methotrexate, vincristine, doxorubicin, and cisplatin) combination chemotherapy. The patient currently shows a radiological partial response without disease progression 10 months after the chemotherapy.
